Ten Boron

Executive Summary

Ten Boron is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on advancing Boron Neutron Capture Therapy (BNCT) for targeted cancer radiotherapy. Founded in 2020, the company develops novel boron-10 delivery agents that selectively accumulate in cancer cells. Upon exposure to low-energy neutron radiation, these agents trigger a localized nuclear reaction that destroys malignant cells while sparing adjacent healthy tissue. BNCT offers a potentially transformative approach for treating radioresistant or disseminated tumors, addressing a significant unmet need in oncology. Currently in Phase 1 clinical development, Ten Boron is evaluating its lead compound in early-stage trials to assess safety, biodistribution, and preliminary efficacy. The company's proprietary boron carriers aim to improve tumor selectivity and pharmacokinetics over historical BNCT agents. With a strong academic heritage and a clear focus on precision oncology, Ten Boron is positioned to capitalize on growing interest in targeted radiotherapies. Key upcoming milestones include initial Phase 1 data readout and potential expansion into larger trials, which will be critical for demonstrating clinical proof of concept and attracting strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and biodistribution data65% success
• Q1 2027FDA/EMA regulatory feedback for Phase 2 trial design70% success
• H2 2026Strategic collaboration or licensing deal40% success